Ovarian Tumor
11
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice
EURAD MRI Classification of US Indeterminate Adnexa Lesions
The Application of Real-Time Near-infrared Imaging in Gynecological Surgery
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
EURAD-MR Classification : European Multicenter Study
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Assess Cancer in Ovarian Tumors With Biomarkers.
Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses